Key Points
- Dyne director Jason Rhodes sold 83,219 shares on May 6 at an average price of $18.18 for proceeds of $1,512,921.42 under a pre-arranged Rule 10b5-1 trading plan.
- Following the sale he now owns 7,962 shares, a reduction of 91.27% of his prior position, valued at roughly $144,749 based on the sale price.
- Dyne recently missed quarterly EPS (‑$0.76 vs. est. ‑$0.74) and analysts forecast FY EPS around ‑2.94; the stock trades near $18.84 with a $3.11B market cap and an average analyst price target of $35.14 despite several recent target cuts.
Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Jason Rhodes sold 11,600 shares of Dyne Therapeutics stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $18.03, for a total transaction of $209,148.00. Following the transaction, the director directly owned 8,390 shares in the company, valued at $151,271.70. This trade represents a 58.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dyne Therapeutics Trading Up 7.8%
NASDAQ DYN opened at $18.84 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 22.25 and a quick ratio of 22.25. The firm's fifty day moving average price is $18.01 and its 200 day moving average price is $18.58. The company has a market capitalization of $3.11 billion, a price-to-earnings ratio of -5.32 and a beta of 1.08. Dyne Therapeutics, Inc. has a 12 month low of $8.06 and a 12 month high of $25.00.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.02). On average, sell-side analysts expect that Dyne Therapeutics, Inc. will post -2.94 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several analysts have recently commented on DYN shares. Chardan Capital restated a "buy" rating and issued a $38.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 9th. Wall Street Zen cut shares of Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, May 2nd. JPMorgan Chase & Co. reduced their target price on shares of Dyne Therapeutics from $17.00 to $16.00 and set a "neutral" rating for the company in a research note on Tuesday, January 20th. Jefferies Financial Group reiterated a "buy" rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Finally, HC Wainwright reduced their price objective on shares of Dyne Therapeutics from $60.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, March 3rd. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.14.
Read Our Latest Research Report on DYN
Institutional Trading of Dyne Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Assetmark Inc. acquired a new stake in shares of Dyne Therapeutics in the first quarter valued at about $563,000. Bank of New York Mellon Corp raised its position in Dyne Therapeutics by 13.6% during the first quarter. Bank of New York Mellon Corp now owns 401,616 shares of the company's stock worth $7,281,000 after acquiring an additional 48,119 shares during the last quarter. Fifth Third Bancorp acquired a new position in Dyne Therapeutics during the first quarter worth about $983,000. Darwin Wealth Management LLC raised its position in Dyne Therapeutics by 34.4% during the first quarter. Darwin Wealth Management LLC now owns 154,862 shares of the company's stock worth $2,808,000 after acquiring an additional 39,595 shares during the last quarter. Finally, Stephens Inc. AR acquired a new position in Dyne Therapeutics during the first quarter worth about $183,000. Institutional investors and hedge funds own 96.68% of the company's stock.
About Dyne Therapeutics
(
Get Free Report)
Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.
Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
